MIGDAL HA'EMEQ, Israel, April 1, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that following a mediation process with Neptune Technologies & Bioressources, Inc. (Nasdaq:NEPT) ("Neptune"), in conjunction with litigation in the U.S. International Trade Commission ("ITC"), and based on latest developments regarding Neptune's patents in the U.S. Patent and Trademark Office ("USPTO"), it has decided that it will not continue its efforts to negotiate a final settlement agreement with Neptune.
Help employers find you! Check out all the jobs and post your resume.
